Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [18F]FDG PET/CT

Diagnostics

卷:11

Dino Rubini¹  Cristina Ferrari¹  Valentina Lavelli¹  Paolo Mammucci¹  Giuseppe Rubini¹  Rossella Ruta¹  Giulia Santo¹  Angela Sardaro² 

[1]Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy

[2]|Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy

关键词: RAI-R;    differentiated thyroid cancer;    multi-tyrosine kinase inhibitors;    positron emission tomography;    PET;    [¹⁸F]FDG PET/CT;   

DOI  :  10.3390/diagnostics11081417

来源: DOAJ

【 摘 要 】

Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[¹⁸F]fluoro-D-glucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [¹⁸F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer.

【 授权许可】

Unknown